ClinicalTrials.gg
CompletedNCT06805513Updated Jul 13, 2026

Actual Use Trial of Tadalafil 5 mg

A Phase 3 interventional study of Tadalafil 5 mg tablets with a digital tool. in Erectile Dysfunction, sponsored by Sanofi. Completed at 1 site in United States. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,212
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
2nd of 56
2,212 · median 199
Started
2025
with 6 others
Phase 3
19 of 57
2 open now
Registered
46th of 57
by date

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 2nd largest by enrollment of the 56 interventional ones that give a count, is one of 7 that started in 2025, is one of 19 in phase 3, and was the 46th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The purpose of this actual use trial (AUT) is to evaluate if participants can appropriately select and use the study product [Cialis over the counter (OTC)] using the labeling and the mandatory health survey assessment (HSA) for duration of 4-months.

Read the detailed description

This will be an open-label 4-month AUT of tadalafil 5 mg tablet in men who are interested in an OTC treatment for erectile dysfunction. The open-label study will enroll approximately 2,250 participants who qualify for treatment based on the data they enter into the HSA of which an estimated 1000 participants will ultimately proceed to the use phase.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants will be included in Part II (enrolment phase) if they are:

  1. Male or female, 16 years of age or older
  2. Living in the US (Since this study will be conducted remotely, it is important to assure that all participants reside in this country.)

Participants will be included in Part III (use phase) if they:

  1. Are male (sex assigned at birth)
  2. Are at least 18 years of age
  3. Complete the HSA with a purchase code for Cialis OTC
  4. Purchase the study product

Exclusion criteria

Exclusion Criteria:

Below participants will be excluded from Part II:

  1. Participant lives in the state of Massachusetts (Massachusetts state law requires an application to the State Board of Pharmacy in order to get authorization to distribute the study product to participants who live there.)
  2. Participant 18 years of age or older is unable or unwilling to show a current government-issued identification (ID) in order to verify identity and age
  3. Participant cannot read, speak, and understand English
  4. Participant has participated in another health-related market research study, product label study, or clinical trial in the past 12 months
  5. Participant has ever participated in a research study about a medicine for erectile dysfunction
  6. Participant, or someone else in the household works for a pharmaceutical company
  7. Participant, or someone else in the household is a healthcare professional, works as a part of a health care practice, or has been trained as a healthcare professional
  8. Participant, or someone else in the household is employed by a market research or advertising company
  9. Participant or someone else in the household is employed by PEGUS Research
  10. Participants will be told that if they need corrective lenses to read, they must have them when the remote Enrollment Interview is conducted (Part II). If they do not, they will not be allowed to participate. This exclusion will be implemented during the remote Subgroup Identification Interview (SGI) Interview where the participants will be re-screened.
  11. Participants who are considered minors, according to the law in the state where they reside, who do not have a parent or guardian present and willing to electronically sign permission to allow the minor to participate in the SGI and Enrollment Interviews. A participant is considered a minor in all states if they are 16-17 years of age. Additionally, participants 18 years of age in Alabama or Nebraska, and participants 18-20 years of age in Mississippi are also considered minors.
  12. Participant is not willing or able to attend/participate in the Enrollment Interview remotely
  13. Participant, or someone else in the household, has participated in this study (only one member of each household will be allowed to participate)
  14. Participant does not provide verbal permission to video record study interviews
  15. If necessary to obtain approximately 30% low health literacy (LHL), participants who are not LHL will be screened out

Below participants will be excluded from Part III:

  1. Participants who were not excluded for DNU conditions in the HSA, but were determined in the Medical Assessment to have any of the DNU conditions listed on the DFL
  2. Participants who do not sign the Document (ICD) or if the parent or guardian of a minor does not sign the ICD. (Parent/guardian refusal applies to males who are 18 years of age or older but considered minors in the state where they reside.)
  3. Participants who are unwilling to provide contact information
  4. Participants who are unwilling or unable to use an eDiary to record the required information
  5. Participants who the principal investigator or the Medical Monitor believes should be excluded or removed from further participation in the Use Phase due to safety concerns
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,212 participants (actual)

Study arms

  • Other
    Cialis OTC

    Open Label Single Arm study in men who have the symptoms of ED and who have an interest in an OTC treatment.

    Combination Product: Tadalafil 5 mg tablets with a digital tool.

Interventions

  • Combination productTadalafil 5 mg tablets with a digital tool.

    Drug page: Tadalafil

    The combination product will be a Drug (Tadalafil 5 mg) and Health Survey Assessment (as a mandatory digital tool). Tadalafil 5 mg will be taken orally, 1 tablet daily to use for treatment of erectile dysfunction. This study will be conducted remotely, via video interaction.

    Also known as: Cialis 5 mg

06

What researchers measure

Primary outcomes

  1. The proportion of inter-dosing intervals in which the recommended time between doses is followed

    Dosing intervals from participant dosing occasions as recorded in the eDiary population will be used to calculate this endpoint.

    Time frame: From the beginning of Use phase to end, at 120 days.

  2. The proportion of all participants found to have a do not use (DNU) condition in the Medical Assessment who also received a DNU Outcome screen in the Health survey assessment

    Time frame: 1 day (completion of the enrollment interview)

Secondary outcomes

  1. Descriptive analysis of care-seeking behaviors in the case of heart attack, priapism, allergic reaction, sudden vision or hearing loss, where the participant took Cialis OTC within the 72 hour time period prior to the event

    Time frame: From the beginning of Use phase to end, at 120 days.

  2. Descriptive analysis of care-seeking behaviors associated with dizziness or feeling faint which does not get better after sitting or lying down, and where the participant took Cialis OTC within the 72 hour time period prior to the event

    Time frame: From the beginning of Use phase to end, at 120 days.

  3. Descriptive analysis of serious adverse event (SAE)s and adverse event of special interest (AESI)s.

    Time frame: From the beginning of Use phase to end, at 150 days (120 days study period + 30 day follow-up period).

  4. Descriptive analysis of dosing behavior patterns among those who do not comply with the recommended dosing interval.

    Time frame: From the beginning of Use phase to end, at 120 days.

  5. The proportion of participants ever prescribed a nitrate medicine who also received a DNU-Nitrate Outcome screen in the HSA.

    Time frame: 1 day (completion of the enrollment interview)

  6. The proportion of all participants found to have ask a doctor before use (AADBU) or ask a doctor or pharmacist before use (AADPBU) conditions in the Medical Assessment who also received an AADBU or AADPBU Outcome screen in the HSA.

    Time frame: 1 day (completion of the enrollment interview)

  7. The proportion of participants who take 1 tablet (5 mg) on the first dosing occasion.

    Time frame: From the beginning of Use phase to end, at 120 days.

  8. The proportion of dosing occasions in which 2 tablets (10 mg) are not exceeded per dosing occasion.

    Time frame: From the beginning of Use phase to end, at 120 days.

07

Study locations

1 site
  • Pegus
    Salt Lake City, Utah 84101, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Mar 2026, 13 months.

Of 16 phase 3 interventional studies under Erectile Dysfunction, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2025
First posted
Feb 3, 2025
StartActual
Jan 30, 2025
Primary completionActual
Mar 2, 2026
CompletionActual
Apr 2, 2026
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06805513
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
Jan 30, 2025
Primary completion
Mar 2, 2026
Completion
Apr 2, 2026
Last update
Jul 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion